JJournal of Allergy and Clinical Immunology3/1/2026Drug screening identifies Src/Abl inhibitor dasatinib as suppressor of IL-23 signaling in skin inflammationM.J. Valle-Pastor·MN Rayo Navarro·J.S. Yebra·J. Traba·A. Oliva·G. Pastor-Fernández·I. Cayuela·L. Senach-RasillaRead at Journal of Allergy and Clinical ImmunologyTagsChronic Myeloid Leukemia TreatmentsHematology
